Genzyme to establish new drug manufacturing plant in Belgium

The new plant will include 8,000 liters of production capacity, a complete purification installation, and ample room for additional future capacity expansions.

Commercial approvals for the new site are expected to start in late 2014.

Genzyme Global Manufacturing and Corporate Operations president Scott Canute said the expansion of Geel facility is a critical element of the manufacturing strategy and is fundamental to their mission.

"We are committed to delivering a reliable supply of high quality medicines to our patients and this investment ensures continued supply to our patients in the Pompe community for the long term," Canute said.